NSC 631570

Drug Profile

NSC 631570

Alternative Names: NSC B238865; Ukrain; UKSR 222; W122

Latest Information Update: 16 Nov 2009

Price : $50

At a glance

  • Originator Nowicky Pharma
  • Developer Military Medical Academy; Nowicky Pharma; Ukrainian Anti-Cancer Institute
  • Class Antineoplastics; Berberine alkaloids; Phenanthridines
  • Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Cancer
  • Clinical Phase Unknown Pancreatic cancer
  • No development reported Influenza virus infections

Most Recent Events

  • 10 Oct 2002 A study has been added to the adverse events and Cancer therapeutic trials sections
  • 08 Jun 1999 A clinical study has been added to the Cancer pharmacodynamics section
  • 08 Jun 1999 Two preclinical studies have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top